The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Biotech a drug discovery engine

| May 29, 2012

We sometimes hear about diminishing returns in cancer research and development in the big pharmaceutical companies. They tell us, traditional drug discovery techniques have picked most of the low-hanging fruit in the field. Cancer cells are tricky devils, able to quickly mutate resistance to our best available therapies.

View the original article here: Biotech a drug discovery engine

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend